Overview

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well pembrolizumab with or without chemotherapy works when given before surgery in treating patients with stage I-IIIA non-small cell lung cancer. Immunotherapy with pembrolizumab, may induce changes in body?s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the cancer prior to surgery and decrease the likelihood of the cancer returning following surgery.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cisplatin
Pembrolizumab
Pemetrexed